The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffness, UACR, endothelial glycocalyx and global longitudinal strain will be assesed at baseline, 4 and 12 months.

NCT Number	NCT06611904
Lead Sponsor	Attikon Hospital
Conditions	Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness
Enrollment	60 participants
Start Date	2018-02-01
Primary Completion	2022-02-05 (estimated)
Study Completion	2024-12-15 (estimated)
Updated on ClinicalTrials.gov	2024-09-25